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Abstract 
Each year over one million patients with acute heart failure (AHF) present to a United States 
emergency department (ED). The vast majority are hospitalized for further management. The length 
of stay and high post-discharge event rate in this cohort has changed little over the last decade. 
Therapeutic trials have failed to yield substantive improvement in post-discharge outcomes, 
subsequently, AHF care has changed little in the last 40 years.  Prior research studies have been 
fragmented as either “inpatient” or “ED-based”. Recognizing the challenges in identification and 
enrollment of ED patients with AHF, and the lack of robust evidence to guide management, an AHF 
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clinical trials network was developed.  This network has demonstrated, through organized 
collaboration between cardiology and emergency medicine, that many of the hurdles in AHF 
research can be overcome. The development of a network that supports the collaboration of acute 
care and HF researchers, combined with the availability of federally funded infrastructure, will 
facilitate more efficient conduct of both explanatory and pragmatic trials in AHF. Yet many 
important questions remain, and in this document our group of emergency medicine and cardiology 
investigators have identified four high priority research areas.   
 
Each year over one million patients with acute heart failure (AHF) present to an emergency 
department (ED) in the United States.1 The vast majority are admitted to the hospital for further 
management.2, 3 While a minority may be discharged from the ED after a short stay and prior 
recommendations suggest who may be safe for management in an observation unit4, no definitive 
guidelines exist to aid clinicians in identifying patients who don’t require hospitalization. The length 
of stay and high post-discharge event rate for AHF patients admitted through the ED and discharged 
from the inpatient setting have changed little over the last decade.5, 6 Therapeutic trials in this clinical 
syndrome have thus far failed to yield any improvement in post-discharge outcomes, including 
recent neutral results from 3 studies evaluating improvements in clinical endpoints such as 
worsening heart failure, dyspnea and mortality.7-10 Since AHF admissions are the number one cause 
of hospitalization for Medicare beneficiaries, accounting for the majority of over 30 billion dollars in 
direct costs, continued research is imperative to improve outcomes of these patients.5 Prior studies 
in patients with AHF were often fragmented as either “inpatient” or “ED-based”. Improved 
collaboration between acute care and HF researchers and the availability of federally funded acute 
care and HF network infrastructure can change this, facilitating the conduct of both pragmatic and 
explanatory trials. Herein, we outline important questions related to the current management of 
AHF whose answers are needed to both inform national guidelines, and improve patient care.  
 
Challenges and Opportunities in Emergency Department Management of Acute Heart Failure  
Finding safe and effective treatments for AHF is a worldwide priority.11, 12 AHF care has changed little 
in the last 40 years, and 80% of patients with AHF are uniformly treated with intravenous (IV) 
diuretics, despite significant heterogeneity of both HF etiology and acute precipitants.13 
Management of AHF is largely based on opinion and experience rather than evidence,14, 15 yet is 
associated with extensive resource utilization and persistently poor outcomes.16-20 The experience 
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with AHF is contrasted with patients with chronic HF with reduced ejection fraction where national 
guidelines give strong I-A recommendations for oral therapies like angiotensin converting enzyme 
inhibitors (ACEI) or angiotensin receptor antagonists (ARB), angiotensin receptor neprilysin 
inhibitors (ARNI), beta blockers, and mineralocorticoid receptor antagonists.21-25  Moreover, after an 
ED visit over 80% of patients with AHF are hospitalized, despite recent studies describing low-risk 
patients being safe for discharge after short-term therapy.1, 26-29 Safely transitioning a larger 
proportion of patients to the outpatient setting is an unmet need.   
 
Priority Topics for Future Research in Acute Heart Failure: Necessary Emergency Medicine and 
Cardiology Collaboration 
Completion of ED-based AHF clinical trials requires a coordinated effort at multiple centers with 
access to patients with AHF. There are challenges in identification and enrollment of ED patients with 
AHF and the lack of evidence guiding their management. It would be crucial for HF and emergency 
medicine investigators to develop local collaborations to help answer these questions by facilitating 
clinical trial enrollment.  One example of this has originated from multidisciplinary partnerships that 
capitalize on robust local site infrastructures at select institutions, creating the first US-based AHF 
clinical trials network.30 The Emergency Medicine Research and Outcomes Consortium (EMROC) 
network requires each participating institution to have a collaborative model, where both an 
emergency medicine physician and cardiology investigator have an ongoing relationship that 
facilitates implementation of clinical care pathways and research initiatives.31  Seamless transition 
from the ED to the inpatient setting also remains an important goal of this network as optimal 
transition ensures patient safety, complete data capture, and ideal interaction between the study 
team and clinical team. This also ensures competitive trials are not separately initiated by the 
emergency medicine and the cardiology investigators, resulting in poor enrollment in both. As new 
studies are considered, the emergency medicine and cardiology investigators determine by 
consensus who will lead the study, whether the population of patients is adequate, and how each 
protocol will be implemented. Obtaining informed consent in a chaotic ED environment, utilizing 
exception from informed consent, and the early enrollment of patients at the time of initial ED 
evaluation are all concepts familiar to EM research teams, but can be challenging for cardiology-
based investigators. Conversely, while it is routine for the cardiology team to manage a study patient 
on the hospital floor or in the intensive care unit, and in the post-discharge clinic environment, this is 
often unfamiliar to many emergency medicine investigators.   
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Having infrastructure already in place engenders timely contract and IRB submission, study 
start up and enrollment, and results in rapid implementation of industry supported and federally 
funded trials by site investigators. Although ED-based teams screen the electronic medical record in 
a similar manner as other hospital based research teams, the most successful ED teams place 
research staff physically in the ED and work with the ED clinical team to identify and approach 
potential participants to gauge their interest. Once a subject candidate is identified to fulfill the 
inclusion and exclusion criteria, and expresses interest in the study, the ED team then confirms the 
availability of the cardiology team to assume inpatient study responsibilities. This model has been 
successful in several AHF studies, accounting for a high volume of enrolled patients relative to the 
number of participating EMROC centers in each study (Table). Given the unique expertise the 
EMROC network provides, it also provides additional opportunities for its participants to serve on 
steering and executive committees for studies. 
While there remain ample opportunities to further understand the epidemiology, taxonomy, 
pathophysiology, treatment options, and approach to disposition for the management of patients 
with AHF, we believe the following targeted topics are of highest priority to advance care. The 
author group held an in-person meeting at the Heart Failure Society of America meeting in 2016 
(Orlando, FL) where ideas were solicited for both our next manuscript topic and the content to be 
contained in the manuscript. We used a nominal group technique (consensus-building methodology 
involving structured, iterative rounds of input to identify, review, prioritize, discuss, and reprioritize 
research domains and questions) to develop the research topics proposed in this consensus document.  
 
1) Does Early Bolus Vasodilator Use Improve Symptoms In Patients With Hypertensive Acute Heart 
Failure? 
Emerging data suggest variable hemodynamic derangements underlie similar clinical presentations 
among AHF patients. In particular, patients with hypertensive AHF have exaggerated 
vasoconstrictive physiology,32, 33 are more likely to have greater fluid redistribution than net fluid 
gain, and appear to benefit from IV vasodilators. Despite this understanding, vasodilators remain 
underutilized.34, 35 Recent trials of IV vasoactive agents have produced neutral results, but have 
largely excluded patients with significant blood pressure elevations.7, 10, 36 Preliminary data in 
hypertensive AHF patients suggests targeting this pathophysiology with IV vasodilators improves 
symptoms, as well as decreases length of stay and resource use.37-41 In patients with chronic HF, 
national guidelines give a strong I-A recommendation for use of oral vasodilators including ACEI and 
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nitrates in select patients. Conversely, in the setting of AHF there are far weaker II-B 
recommendations for the use of nitroglycerin (NTG) or other IV vasodilators, and the precise 
patients in whom this therapy needs to be utilized is poorly characterized.21-25 The lack of robust data, 
combined with the additional monitoring and titration necessary for continuous vasodilator 
infusions, leads to their infrequent use in AHF, even when hypertension is a predominant 
component. Early vasodilator use in hypertensive AHF seems logical, and IV boluses instead of 
continuous drips may facilitate improved outcomes and resource use. A rigorously designed study is 
necessary to provide strong evidence for their appropriate and safe use, and ultimately to drive 
practice change.22, 34, 42, 43 Preliminary data suggest the early use of bolus IV ACEI and bolus high-dose 
(HD) NTG would benefit patients with hypertensive AHF.38-40 Despite promising preliminary data, a 
randomized trial comparing bolus IV ACEI and IV HD NTG with structured standard therapy is needed 
to determine the clinical impact and safety of this approach. 
 
2) Can Utilization of Objective Targets of Decongestion Lead to Improve Clinical Outcomes?  
Mortality and symptoms have been the focus of AHF clinical trials, irrespective of mechanism of 
action or phase of therapy development. However, it is not clear what the optimal combination 
should be for a primary endpoint. Symptoms related to congestion, due to fluid gain and/or 
redistribution, are the primary reason patients with AHF present to the ED. For many, symptoms can 
often be reduced with the use of standard IV diuretics, but failure to completely relieve congestion is 
associated with worse outcomes. Up to 50% of patients with AHF leave the hospital with persistent 
congestion.44-46 Both the assessment and treatment of congestion is based on limited evidence11, 12, 47-
49 and current guidelines state that “the treatment of AHF remains largely opinion-based with little 
good evidence to guide therapy.”48  
 
Combining an objective measure of decreased congestion with subjective improvement, 
such as dyspnea assessment, may lead to better identification of optimal treatment endpoints. 
Following changes in natriuretic peptides during hospitalization to identify treatment endpoints have 
not proven beneficial.50 However, lung ultrasound can identify congestion and pulmonary edema 
with high sensitivity51 and discriminate AHF from other causes of dyspnea. Beyond its diagnostic 
value, lung ultrasound demonstrates changes in pulmonary edema in real time.52-54 Improvement in 
sonographic pulmonary edema has been shown during dialysis53, 54 and in response to inpatient AHF 
treatment.52, 55-57 Incomplete resolution of pulmonary edema visualized on lung ultrasound following 
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inpatient treatment predicts the need for re-hospitalization.57, 58 Given the prognostic value of 
residual sonographic pulmonary edema, its resolution may be a valuable therapeutic target for both 
routine and investigational AHF therapy and merits further investigation.  
Other metrics such as inferior vena cava ultrasound also deserve study. A prospective, multi-
center study comparing length of stay, 30-day readmission and mortality between patients 
randomized to: 1) routine clinical treatment or 2) treatment directed by serial lung ultrasound 
measures of congestion, or other objective measures, would determine if these strategies better 
define therapeutic endpoints. A large, clinically heterogeneous cohort would allow for subgroup 
analyses of patients with heart failure and reduced vs. preserved ejection fraction, those presenting 
with differences in initial blood pressure, and relevant comorbidities such as diabetes and chronic 
kidney disease. ED lung fluid assessment may facilitate optimal disposition to the observation unit, or 
the medical floor, vs. other inpatient settings, and repeated assessment may provide an objective 
measure of ‘readiness for discharge’.59-61  
 
3) Can Use of Non-Invasive Physiological Monitoring Facilitate Emergency Department Care and Safe 
Discharge? 
Remote monitoring technologies can help engage subjects, inform caregivers, and facilitate timely 
intervention. These technologies have been utilized to manage patients with HF in an effort to 
improve quality of life and prevent readmissions.62-64 However, most of these studies have utilized 
indwelling sensors in chronic ambulatory patients to acquire and relay the information to the patient 
and their providers.65 This limits the utility and generalizability of this technology to patients with 
implanted devices, and their utility in the ED patient with AHF is unclear. There are currently available 
external monitoring devices that collect data such as chest impedance, radar volume detection, 
heart rate variability, cardiac index, arrhythmia burden, positionality, and activity levels, similar to the 
implantable devices.60, 66, 67 However, these devices have not yet been broadly and systematically 
studied in the context of AHF in the ED and this represents a tremendous knowledge gap and 
opportunity.  
To accurately utilize such information in ED patients with AHF, it is important to obtain data 
along a continuum from ED presentation through hospitalization and into the post-discharge period. 
These data are critical to quantify decongestion during hospitalization, identify decompensation, and 
predict subsequent re-hospitalization. HF rehospitalization shortly after hospital discharge is a 
unique problem caused by a combination of the disease state and the patient’s ability to navigate the 
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outpatient setting. This may be strongly influenced by patient factors such as medication and dietary 
adherence, health literacy, access to follow-up and socio-economic conditions.2 It would be 
important to test the feasibility of treatment adjustment based on physiologic data from an external 
device applied in the ED and utilized throughout hospitalization and during post-discharge follow-up. 
This would require ED, inpatient, and outpatient providers to establish protocols to ensure 
consistent treatment as a response to changes in the physiologic data. We hypothesize that 
management based on physiologic parameters will result in a decrease in ED visits and hospital re-
admissions compared to patients managed without this information. This type of study could also 
incorporate not only diagnostic data but also therapeutic options whose intensity would be based on 
the severity of physiologic disturbances as indicated by the monitoring. For example, a device able to 
administer subcutaneous diuretic may safely increase the proportion of ED and OU patients who are 
discharged without hospitalization and facilitate symptom improvement in the outpatient setting. In 
addition, combining an external device with an intervention while engaging the patient and their 
caregiver to improve self-care may address the socioeconomic and demographic barriers 
contributing to rehospitalization.68 
 
4) Do All AHF Patients With a Troponin Elevation Absent Suspected Acute Coronary Syndrome Require 
Admission to the Hospital?   
With the development of increasingly sensitive assays, only a minority of patients with AHF will have 
a cardiac specific troponin (cTn) concentration below the 99th percentile of a normal population.69, 70 
The detection of cTn above this cutpoint in the setting of AHF is indicative of some degree of 
underlying myocardial cell death, though release from cytosolic pools in damaged but viable 
cardiomyocytes and other mechanisms have been proposed.71-74 While the presence of serum 
troponin above the 99th percentile occurs in the setting of an acute coronary syndrome (ACS), many 
other causes of cell death are common as well, and may reflect processes more chronic in nature 
involving remodeling with cardiomyocyte turnover.75, 76 cTn concentrations exceeding normal values 
do portend worse prognosis. 26, 29, 77, 78 As a result, clinicians are compelled to treat such patients as 
high-risk, often admitting them to a monitored hospital setting for presumed management of 
possible ACS. However, few such patients actually undergo diagnostic evaluation for potential 
myocardial ischemia and most spend several days in the hospital receiving treatment primarily with 
diuretics. 1, 79 
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It is unclear what the incremental value of hospital admission is in patients who present to 
the ED with AHF, whose symptoms resolve yet are admitted solely due to an elevated cTn. For those 
with new-onset HF, hospitalization to search for underlying, undetected coronary artery disease is 
appropriate, but many patients with AHF have an established diagnosis of chronic HF with known 
previous coronary disease evaluation. Similarly, whether and when such repeat evaluations are 
needed in the presence of a cTn elevation where ACS is unlikely, especially those patients with 
known normal coronary arteries on prior cardiac catheterization, is not clear. In reality, invasive 
studies are often not conducted despite hospitalization for such concerns.80 Moreover, it is not clear 
that hospitalization mitigates risk of outcomes for patients with chronic HF. Prior studies suggest 
few in-hospital cardiac arrest events among those admitted for acute decompensation,81 and no 
difference in 30-day outcome between those admitted compared with those discharged from the 
ED.82 
Given these many unanswered questions regarding optimal disposition decision making, a 
trial focused on safe discharge of ED patients with AHF and stable cTn elevations could alter the 
current clinical practice of hospital admission in many of these patients. Patients with an elevated 
cTn whom the treating ED provider intended to admit, who didn’t have ACS or another acute 
indication for hospital admission, would be randomized to: 1) a usual care arm, which would continue 
with inpatient admission; or 2) an investigational arm prompting discharge from the ED after serial 
cTn assessments prove to be stable. To alleviate clinician concerns about safety, the latter would 
need to include early outpatient follow-up and initiation, re-initiation, or uptitration of appropriate, 
guideline directed medical therapy. To avoid imbalance, case matching or stratified randomization 
may also be needed to account for other risk modifiers such as renal function, blood pressure, and 
psychosocial support.  Given the known trepidation and conservative approach that emergency 
physicians apply to AHF disposition,83 the results of this trial could have a significant impact on 
clinical care.  
 
Answers Require Emergency Medicine and Cardiology Collaboration  
 
Conclusion 
Over the last decade, emergency physicians and cardiologists have partnered to conduct AHF clinical 
trials. This partnership ensures: 1) early patient identification and enrollment; 2) a smooth transition 
for clinical care; and 3) data collection and follow-up for both the inpatient and outpatient setting. 
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This clinical trial infrastructure has been utilized to evaluate novel therapies and optimal ED-based 
management strategies. Such partnerships should continue to be encouraged and further 
strengthened. The outcomes for patients with AHF remain sub-optimal and management guidelines 
remain largely opinion based. Many important questions need to be answered. In this document, our 
AHF Working Group has identified four high priority areas for research including defining optimal 
endpoints of therapy, defining risk and management strategies in AHF patients with elevated cTn, 
and early therapeutic approaches in patients with elevated blood pressure and AHF. Results from 
these studies will inform clinical practice and national guidelines by significantly advancing the 
limited current evidence base.   
 
Table. EMROC participation in AHF studies, study design and number of patients enrolled.  
Study Name Funding 
Entity 
Study 
Type 
Study 
Status 
Total 
Patients 
Enrolled  
US 
patients 
enrolled 
EMROC sites 
- patients 
enrolled  
RELAX AHF 2 Novartis Phase III 
RCT 
Complete 6610 712 115 
TRUE Cardiorentis Phase III 
RCT 
Complete 2152 301 62 
STAND UP BMS Phase 
IIb RCT 
Started 
5/2017 
6 (Approx. 
200 
planned) 
6 3 
GUIDED  PCORI Phase III 
RCT 
Ongoing 700 planned 290  250 
AHF Registry  EMROC Cohort Ongoing 1300 1300 1300 
BLUSHED  
AHF 
NHLBI Phase III 
RCT 
Started 
8/1/17 
135 planned 4 4 
Obs Unit vs Inpatient 
Admission in ED 
patients with AHF 
AHRQ Phase III
RCT 
Pending Pending Pending Pending
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